PMID- 20955379
OWN - NLM
STAT- MEDLINE
DCOM- 20110204
LR  - 20220316
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 57
IP  - 4
DP  - 2010 Oct
TI  - Neoangiogenesis in laryngeal carcinoma: angiogenin and CD105 expression is 
      related to carcinoma recurrence rate and disease-free survival.
PG  - 535-43
LID - 10.1111/j.1365-2559.2010.03664.x [doi]
AB  - AIMS:   Angiogenin regulates angiogenesis supporting primary and metastatic 
      tumour growth. CD105 is a proliferation-associated protein expressed in 
      angiogenic endothelial cells. The aim of this study was to investigate for the 
      first time angiogenin expression in laryngeal squamous cell carcinoma (LSCC) and 
      to evaluate the relationship between angiogenin and CD105 expression, 
      clinicopathological and prognostic parameters. METHODS AND RESULTS:   A total of 
      108 consecutive operable LSCCs were studied. Angiogenin expression was determined 
      immunohistochemically in both carcinoma cells and intratumoral vessels. CD105 
      expression was evaluated in endothelial cells of LSCC and calculated by a 
      computer-based image analysis system. The percentage of the fields occupied by 
      CD105-assessed microvessels was determined. Angiogenin expression in carcinoma 
      cells was higher in LSCC patients who experienced loco-regional recurrence of 
      disease (P=0.032). Disease-free survival (DFS) was shorter in cases with 
      carcinoma cells showing angiogenin expression >21.0% (P=0.035). Angiogenin 
      expression in carcinoma cells was correlated strongly with the angiogenin score 
      in endothelial cells of intratumoral vessels (P=0.0000). Higher loco-regional 
      carcinoma recurrence rate and shorter DFS in patients with high CD105 expression 
      were found (P=0.0004, P=0.0001). CONCLUSIONS:   Angiogenin expression in 
      laryngeal carcinoma cells and CD105 expression can be considered as potentially 
      useful to detect LSCC patients with higher risk of disease recurrence who might 
      benefit from more aggressive therapy.
CI  - (c) 2010 Blackwell Publishing Limited.
FAU - Marioni, Gino
AU  - Marioni G
AD  - Department of Medical and Surgical Specialties, Section of Otolaryngology, 
      University of Padova Department of Medical/Diagnostic Sciences and Special 
      Therapies, Section of Anatomic Pathology, University of Padova, Padova, Italy. 
      gino.marioni@unipd.it
FAU - Marino, Filippo
AU  - Marino F
FAU - Blandamura, Stella
AU  - Blandamura S
FAU - D'Alessandro, Emiliano
AU  - D'Alessandro E
FAU - Giacomelli, Luciano
AU  - Giacomelli L
FAU - Guzzardo, Vincenza
AU  - Guzzardo V
FAU - Lionello, Marco
AU  - Lionello M
FAU - De Filippis, Cosimo
AU  - De Filippis C
FAU - Staffieri, Alberto
AU  - Staffieri A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (ENG protein, human)
RN  - 0 (Endoglin)
RN  - 0 (Receptors, Cell Surface)
RN  - EC 3.1.27.- (angiogenin)
RN  - EC 3.1.27.5 (Ribonuclease, Pancreatic)
SB  - IM
MH  - Aged
MH  - Antigens, CD/*biosynthesis
MH  - Biomarkers, Tumor/analysis
MH  - Carcinoma, Squamous Cell/metabolism/mortality/*pathology
MH  - Disease-Free Survival
MH  - Endoglin
MH  - Female
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/metabolism/mortality/*pathology
MH  - Male
MH  - Neoplasm Recurrence, Local/metabolism/pathology
MH  - Neoplasm Staging
MH  - Neovascularization, Pathologic/metabolism/mortality/*pathology
MH  - Receptors, Cell Surface/*biosynthesis
MH  - Ribonuclease, Pancreatic/*biosynthesis
EDAT- 2010/10/20 06:00
MHDA- 2011/02/05 06:00
CRDT- 2010/10/20 06:00
PHST- 2010/10/20 06:00 [entrez]
PHST- 2010/10/20 06:00 [pubmed]
PHST- 2011/02/05 06:00 [medline]
AID - 10.1111/j.1365-2559.2010.03664.x [doi]
PST - ppublish
SO  - Histopathology. 2010 Oct;57(4):535-43. doi: 10.1111/j.1365-2559.2010.03664.x.